MedTrace Logo

Efficacy and Safety of T+A+RAD in HCC

NCT05396937 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-05-31

No results posted yet for this study

Summary

This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma

Conditions

Interventions

RADIATION

Multifocal Stereotactic Radiotherapy

Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.

DRUG

Atezolizumab Injection [Tecentriq]

Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle

DRUG

Bevacizumab

Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Principal Investigators

  • Lu Wang · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05396937 on ClinicalTrials.gov